Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab

BACKGROUND: Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Patient
Main Authors: van Rhee, Frits, Rothman, Margaret, Ho, Kai Fai, Fleming, Sarah, Wong, Raymond S., Fosså, Alexander, Dispenzieri, Angela, Cavet, James, Munshi, Nikhil, Vermeulen, Jessica, Casper, Corey
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2015
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4383814/
https://ncbi.nlm.nih.gov/pubmed/25736164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40271-015-0120-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados